5 questions answered from cited research · Plain language
Brolucizumab and aflibercept both improve vision in diabetic macular edema, but brolucizumab may allow longer intervals between injections while carrying a higher risk of intraocular inflammation.
Read the full answer →Yes, aflibercept biosimilars are as safe and effective as the original drug for diabetic macular edema, based on a systematic review and meta-analysis.
Read the full answer →Yes, taking aflibercept every 8 weeks maintains vision gains in diabetic macular edema, as shown in a 96-week trial where the 2 mg every 8 weeks regimen kept visual improvements comparable to extended dosing of 8 mg.
Read the full answer →Yes, Pavblu (aflibercept) is FDA-approved for treating diabetic macular edema (DME).
Read the full answer →Yes, early studies show suprachoroidal injections of triamcinolone can improve vision and reduce swelling in diabetic macular edema, but more research is needed.
Read the full answer →